News

Researchers have closely monitored the evolution of the virus in two chronic patients undergoing combination therapy with the antiviral agent ribavirin and sofosbuvir, which was developed to combat hepatitis C.

Targeting the mTOR signaling pathway could treat sarcoidosis – an inflammatory disease – researchers discover in a new study.

GLP1 agonists like Ozempic have been associated with a reduced risk of cirrhosis and liver cancer in people with type 2 diabetes and chronic liver disease.

Researchers have found that a compound originally developed as a potential cancer treatment holds promise for treating polycystic kidney disease.

Antiviral drugs used to fight HIV were shown to prevent these dangerous complications of infection. Insights into the mechanisms that lead to abscess formation open the door for new lines of thought about treating bacterial infections.

New WSU research could ultimately help extend the lives of those with prostate cancer, one of the leading causes of cancer deaths among men.

Researchers have developed an oral form of insulin that lowers glucose levels in animal models. The oral insulin, encased in a nano-carrier that delivers insulin to the liver, is expected to begin human trials in 2025.

How, exactly, DMT alters brain function to produce positive effects observed in clinical trials is not yet clear, though a study from scientists at Imperial College London has shed some light.

Purdue researchers have created molecular compounds to inhibit protein aggregation linked with Alzheimer’s disease, Parkinson’s disease and Type 2 diabetes.

A traditional African psychedelic drug reduced symptoms of veterans’ brain injury in a small clinical study published in Nature Medicine.